Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reducing treatment duration in patients infected with hepatitis C genotype 1: any need for further studies?

Antiviral therapy - 1 Jan 2009

Craxì Antonio

Abstract excerpt

The recommended treatment duration with pegylated interferon-alpha plus ribavirin for patients infected with hepatitis C virus (HCV) genotype 1 is 48 weeks. Interestingly, a subpopulation of genotype 1 patients experience rapid decreases in HCV RNA levels once treatment is initiated and attain rapid virological response, defined as undetectable HCV RNA at week 4 of therapy. Several studies have shown that these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Drug Administration Schedule
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 20032534
DOI: 10.3851/IMP1428

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reducing treatment duration in patients infected with hepatitis C genotype 1: any need for further studies?PMID 20032534Read ↗

Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis.Semantic proximity Read ↗

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.Semantic proximity Read ↗

Expert opinion on the treatment of patients with chronic hepatitis C.Semantic proximity Read ↗

Optimal treatment duration for patients with HCV genotype 1 infection.Semantic proximity Read ↗

Chronic hepatitis C therapy: changing the rules of duration.Semantic proximity Read ↗

Optimal therapy in genotype 1 patients.Semantic proximity Read ↗

Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it.Semantic proximity Read ↗

No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection.Semantic proximity Read ↗

What is the optimal duration of therapy in patients with hepatitis C genotype 2 or 3 infection?: a review.Semantic proximity Read ↗

Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4.Semantic proximity Read ↗

Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3.Semantic proximity Read ↗

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.